ArticleJournal of clinical microbiology2010
Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling.
Article in Journal of clinical microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 120 citations in OpenAlex.
- Clinical evaluation of rapid fluorescent diagnostic immunochromatographic test for influenza A virus (H1N1).Scientific reports · 2018Trial
- Antigen anisotropy: The overlooked geometric determinant of vaccine immunogenicity and fidelity.Human vaccines & immunotherapeutics · 2026Review
- Sulfur-containing class of broad-spectrum antivirals improves influenza virus vaccine development.Nature communications · 2026Article
- Human immune organoids to decode B cell response in healthy donors and patients with lymphoma.Nature materials · 2025Article
- Boosting neuraminidase immunity in the presence of hemagglutinin with the next generation of influenza vaccines.NPJ vaccines · 2024Article
- A Novel Application of Virus Like Particles in the Hemagglutination Inhibition Assay.International journal of molecular sciences · 2024Article
- Ventricular-subventricular zone stem cell niche adaptations in a mouse model of post-infectious hydrocephalus.Frontiers in neuroscience · 2024Article
- Pre-existing Fc profiles shape the evolution of neutralizing antibody breadth following influenza vaccination.Cell reports. Medicine · 2023Article
- Tethered Bilayer Lipid Membrane Platform for Screening Triton X-100 Detergent Replacements by Electrochemical Impedance Spectroscopy.Nanomaterials (Basel, Switzerland) · 2023Article
- Rapid and reliable inactivation protocols for the diagnostics of emerging viruses: The example of SARS-CoV-2 and monkeypox virus.Journal of medical virology · 2023Article
- Heterologous prime-boost H1N1 vaccination exacerbates disease following challenge with a mismatched H1N2 influenza virus in the swine model.Frontiers in immunology · 2023Article
- PA-X protein of H1N1 subtype influenza virus disables the nasal mucosal dendritic cells for strengthening virulence.Virulence · 2022Article
- Testing of a mobile heating facility to sanitize N-95 respirators against an enveloped respiratory virus.International journal of circumpolar health · 2022Article
- Effects of electromagnetic waves on pathogenic viruses and relevant mechanisms: a review.Virology journal · 2022Review
- Intranasal Treatment of Ferrets with Inert Bacterial Spores Reduces Disease Caused by a Challenging H7N9 Avian Influenza Virus.Vaccines · 2022Article
- Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes.Pathogens (Basel, Switzerland) · 2022Review
- Review of air disinfection approaches and proposal for thermal inactivation of airborne viruses as a life-style and an instrument to fight pandemics.Applied thermal engineering · 2022Review
- Assays for Determining the Sialidase Activity of Influenza Viruses and Monitoring Influenza Virus Susceptibility to Neuraminidase Inhibitors.Methods in molecular biology (Clifton, N.J.) · 2022Article
- MAGI1 inhibits interferon signaling to promote influenza A infection.Frontiers in cardiovascular medicine · 2022Article
- Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities.Vaccines · 2021Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction of a new influenza virus in humans urges quick analysis of its virological and immunological characteristics to determine the impact on public health and to develop protective measures for the human population. At present, however, the necessity of executing pandemic influenza virus research under biosafety level 3 (BSL-3) high-containment conditions severely hampers timely characterization of such viruses. We tested heat, formalin, Triton X-100, and beta-propiolactone treatments for their potencies in inactivating human influenza A(H3N2) and avian A(H7N3) viruses, as well as seasonal and pandemic A(H1N1) virus isolates, while allowing the specimens to retain their virological and immunological properties. Successful heat inactivation coincided with the loss of hemagglutinin (HA) and neuraminidase (NA) characteristics, and beta-propiolactone inactivation reduced the hemagglutination titer and NA activity of the human influenza virus 10-fold or more. Although Triton X-100 treatment resulted in inconsistent HA activity, the NA activities in culture supernatants were enhanced consistently. Nonetheless, formalin treatment permitted the best retention of HA and NA properties. Triton X-100 treatment proved to be the easiest-to-use influenza virus inactivation protocol for application in combination with phenotypic NA inhibitor susceptibility assays, while formalin treatment preserved B-cell and T-cell epitope antigenicity, allowing the detection of both humoral and cellular immune responses. In conclusion, we demonstrated successful influenza virus characterization using formalin- and Triton X-100-inactivated virus samples. Application of these inactivation protocols limits work under BSL-3 conditions to virus culture, thus enabling more timely determination of public health impact and development of protective measures when a new influenza virus, e.g., pandemic A(H1N1)v virus, is introduced in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.